Immunotherapy for ovarian cancer: recent advances and perspectives.

Détails

ID Serval
serval:BIB_0D9F55B9E77A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Immunotherapy for ovarian cancer: recent advances and perspectives.
Périodique
Current opinion in oncology
Auteur(s)
Zsiros E., Tanyi J., Balint K., Kandalaft L.E.
ISSN
1531-703X (Electronic)
ISSN-L
1040-8746
Statut éditorial
Publié
Date de publication
09/2014
Peer-reviewed
Oui
Volume
26
Numéro
5
Pages
492-500
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Epithelial ovarian cancer is the most frequent cause of gynecologic cancer-related mortality in women, and prognosis for patients with recurrent or metastatic disease is extremely poor. Therefore, there is an enormous unmet need for the development of novel therapies in this indication. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies, such as immunotherapy to improve the outcomes for patients with advanced ovarian cancer.
We will discuss the rationale of immunotherapy and some of the mechanisms of immunogenicity in ovarian cancer. We will highlight current results with cancer vaccines, adoptive T-cell therapy and immunomodulatory agents and will summarize the immune effects of selected chemotherapeutic agents, radiotherapy and recent results with combinatorial approaches in this disease setting. We will also discuss recent and potential future therapeutic interventions that might circumvent tumor-mediated immunosuppression.
Dramatic increase in the number of immunotherapy clinical trials was seen in the past decade with promising results in enhancing antitumor immune response and cancer vaccine efficacy. The future challenge for immunotherapy against ovarian cancer is to use a combinatorial approach to test rational, potentially synergistic immunotherapy combinations that can induce efficient antitumor immunity and prolong patients' survival.

Mots-clé
Female, Humans, Immunotherapy, Ovarian Neoplasms/drug therapy, Ovarian Neoplasms/immunology, Ovarian Neoplasms/radiotherapy, Ovarian Neoplasms/therapy
Pubmed
Web of science
Création de la notice
09/02/2018 16:21
Dernière modification de la notice
03/03/2018 13:40
Données d'usage